1. Body JJ, Diel IJ, Lichinitzer M, Lazarev A, Pecherstorfer M, Bell R, Tripathy D, Bergstrom B. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two ran-domized, placebo-controlled phase III studies. Br J Cancer. 2004 Mar 22;90(6):1133-7.
2. Tripathy D, Lichinitzer M, Lazarev A, MacLachlan SA, Apffelstaedt J, Budde M, Bergstrom B; MF 4434 Study Group. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol. 2004 May;15(5):743-50.
3. Pavlakis N, Schmidt RL, Stocler M. Bisphosphonates for breast cancer (Review). Cochrane database of systematic reviews 2005, Issue 3.
РОНЦ им. Н.Н. Блохина РАМН
1 Отделение химиотерапии и комбинированного лечения злокачественных опухолей
2 Отделение лучевой терапии
3 Лаборатория биохимии
4 Отделение лучевой диагностики
5 Отделение радиоизотопной диагностики